{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-010409","form_type":"8-K","ticker":"DMAC","cik":"0001401040","company_name":"DiaMedica Therapeutics Inc.","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.990613+00:00","generated_at":"2026-05-15T08:07:54.062912+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DiaMedica reports FY2025 cash $59.9M; ReMEDy2 trial nearing 70% interim enrollment","bullets":["Cash and investments $59.9M at Dec 31, 2025, up from $44.1M; runway through 2H 2027.","ReMEDy2 Phase 2/3 AIS trial approaching 70% of required interim enrollment; analysis in 2H 2026.","R&D expenses $24.6M vs $19.1M YoY driven by ReMEDy2 expansion and PE program costs.","G&A expenses $9.8M vs $7.6M YoY; net cash used in ops $29.1M vs $22.1M.","PE Phase 2 IST Part 1a enrollment ongoing; DiaMedica-sponsored Phase 2 to start later 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-010409","json":"https://secwatch.observer/filing/0001437749-26-010409.json","markdown":"https://secwatch.observer/filing/0001437749-26-010409.md","text":"https://secwatch.observer/filing/0001437749-26-010409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/0001437749-26-010409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/dmtp20260330_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:07:54.062912+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0ceadbc6f270c3c8ffa382c0172054ca8fad7da","claim":"DiaMedica Therapeutics Inc. reported financial results for the year ended December 31, 2025.","evidence_excerpt":"On March 30, 2026, DiaMedica Therapeutics Inc. (the \"Company\") announced its consolidated financial results for the year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/0001437749-26-010409-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}